Prestige BioPharma Limited (KRX:950210)

South Korea · Delayed Price · Currency is KRW

5,640.00

-320.00 (-5.37%)

Oct 12, 2026, 3:30 PM KST

Prestige BioPharma Financials Overview

Financials in millions KRW. Fiscal year is July - June.

Millions KRW. Fiscal year is Jul - Jun.

Revenue & Profits

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Revenue	26,072	26,072	14,326	689.08	161.84	-
Revenue Growth	81.99%	81.99%	1978.97%	325.77%	-	-
Gross Profit	-16,232	-16,232	-12,237	-10,602	127.9	-228.95
Operating Income	-93,422	-93,422	-66,585	-62,238	1,034	-122,689
Net Income	-91,499	-91,499	22,297	-32,921	17,569	-211,450
Earnings Per Share	-1522.60	-1522.60	371.00	-549.00	292.35	-3796.17
EPS Growth	-	-	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Cash & Investments	65,954	65,954	178,702	222,492	301,412	303,270
Total Debt	106,734	106,734	151,612	89,667	115,561	4,249
Net Cash (Debt)	-40,780	-40,780	27,090	132,825	185,851	299,020
Net Cash Growth	-	-	-79.60%	-28.53%	-37.85%	-33.78%
Net Cash Per Share	-678.57	-678.57	450.78	2215.00	3092.56	4975.70

Cash Flow & CapEx

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Operating Cash Flow	-55,818	-55,818	-52,135	-48,027	-60,274	-45,907
Capital Expenditures	-5,972	-5,972	-40,742	-20,063	-48,363	-56,429
Free Cash Flow	-61,790	-61,790	-92,877	-68,091	-108,636	-102,336
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Gross Margin	-62.26%	-62.26%	-85.42%	-	79.03%	-
Operating Margin	-358.33%	-358.33%	-464.80%	-9032.13%	639.01%	-
Pretax Margin	-471.95%	-471.95%	27.38%	-7936.63%	-1294.78%	-
Profit Margin	-350.95%	-350.95%	155.64%	-4777.60%	10855.90%	-
FCF Margin	-237.00%	-237.00%	-648.33%	-9881.47%	-67125.45%	-

Valuation

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct '26 Oct 12, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
PE Ratio	-	-	7.92	-	6.47	-
Forward PE	-	12.01	12.01	12.01	12.01	12.01
PS Ratio	2.60	2.98	12.33	150.88	701.81	-